Researchers who have published a large UK trial to see if the COVID-19 vaccine can be safely mixed has been expanded to include injections made by Moderna and Novavax. , the researchers announced Wednesday.
vaccine, a few weeks later, is a one made by the pharmaceutical company Pfizer
and BioNTech biotechnology
and vice versa.
The extensive research will look for adults over 50 years of age who have received their first vaccinations in the past 8 to 12 weeks.
These volunteers, who will receive a vaccine from the pharmaceutical company AstraZeneca, developed with Oxford University, or the Pfizer-BioNTech vaccine, will be randomly given the same shot or from technology Moderna biology
or from Novavax pharmaceuticals
for the second dose.
Six new “arms” of the trial, each “arm” will have the participation of 175 people, bringing the total number of participants to the test to 1,050 people.
Working across eight locations in the UK, researchers will track the immune system’s response, as well as any adverse reactions, such as fever, to the new combination vaccines. this. The test is designed as a study called ‘no less quality’, which means its purpose is to demonstrate that mixing is not fundamentally worse than not mixing.
“If we can demonstrate that these mixed schedules produce as good an immune response as the standard schedule and do not have a significant increase in vaccine response, then this has the potential to allow for more people complete their COVID-19 vaccination course faster, ”said Matthew Snape, associate professor of pediatrics and immunization at Oxford University and lead investigator of the trial, said in a statement.
“This will also create resilience in the system in the event of a supply shortage of any vaccine,” added Snape.
Extensive research comes after the rollout of Moderna vaccine in UK started this week across UK
Novavax vaccine was found to be 96% effective in preventing cases caused by the original version of coronavirus causing COVID-19 in a late stage trial conducted in the UK. is produced with the assistance of GlaxoSmithKline pharmaceuticals
in the UK, is not yet approved and is under review by the Pharmaceutical and Healthcare Products Regulatory Authority (MHRA).
Results from the initial Com-Cov trial, using only the AstraZeneca and Pfizer – BioNTech vaccines, are expected in May, while the results for phase two will be announced in June or July. though the study will last for a year.
If it shows promising results, MHRA and Joint Commission on Immunization and Immunization will formally evaluate the safety and efficacy of any new immunization regimen before applying it to a patient.